|
- Home
- Join or Change Subscription
- GSI Community
- For New GIST Patients
- About GIST
- Pediatric GIST & Carney Triad
- Treatments for GIST
- Ask the Professional
- Learning Center
- Voices of GIST
- Educational Materials
- GIST Support Wiki
- Donate
- Financial Assistance
 | |
 | |
R1507
This anti-IGF-1R inhibitor is no longer under development. Some trials are ongoing but no longer recruiting.
manufacturer website link: Roche / Genmab
oral or intravenous: Intravenous
Description from NCI Drug Dictionary: A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Anti-IGF-1R human monoclonal antibody R1507 binds to membrane-bound IGF-1R, preventing the binding of the natural ligand IGF-1 and the activation of PI3K/AKT signal transduction; downregulation of the PI3K/AKT survival pathway may result in the induction of apoptosis and decreased cellular proliferation. The activation of IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.
Ongoing Trials:
A Study of R1507 in Patients With Recurrent or Refractory Sarcoma (Phase II, NCT00615680)
A Study of R1507 in Patients With Recurrent or Refractory Sarcoma (NCT00642941)
A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors
(NCT00560144)
A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors. (NCT00400361)
